{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:20:08Z","timestamp":1793305208185,"version":"4.5.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Epilepsy is a common symptom in patients with brain metastases (BMs), and because of the rising incidence of BMs, adequate seizure management is warranted. We conducted a systematic review on seizure outcomes after antitumor treatment and antiseizure medication (ASM) in patients with BMs from solid tumors and epilepsy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A literature search was performed in 6 databases up to February 2024. Extracted outcomes were rates for (1) seizure freedom, (2) \u226550% seizure reduction, and (3) treatment failure (for ASM only). Weighted averages (WAs) were calculated for outcomes after surgery at 6 months follow-up. Quality assessment of the included studies was performed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We retrieved 2244 references, of which 16 studies were eligible for inclusion. Eight studies were at critical, and 8 studies at serious risk of bias. The WA of seizure freedom rates at 6 months after surgical resection was 64% (based on 3 studies at serious risk of bias, n\u2005=\u2005151 patients). Results on ASM efficacy and tolerability were unreliable, as all eligible studies for these outcomes were at critical risk of bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Limited available evidence from heterogeneous study populations demonstrated that in the majority of patients with epilepsy due to BMs, seizure freedom 6 months after surgical resection may be reached. No substantial evidence on ASM efficacy and tolerability in patients with epilepsy due to BMs is available. High-quality cohort studies are warranted to expand the evidence on seizure outcomes after antitumor and ASM treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npae103","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:29:30Z","timestamp":1729596570000},"page":"376-388","source":"Crossref","is-referenced-by-count":5,"title":["Seizure outcomes in patients with brain metastases and epilepsy: a systematic review on the efficacy of antitumor treatment and antiseizure medication"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9403-9947","authenticated-orcid":false,"given":"Josien C C","family":"Scheepens","sequence":"first","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim B","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9895","authenticated-orcid":false,"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike J","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Haaglanden Medical Center , The Hague ,","place":["the Netherlands"]},{"name":"Department of Neurology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J B","family":"Taphoorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A F","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Haaglanden Medical Center , The Hague ,","place":["the Netherlands"]},{"name":"Department of Neurology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"issue":"1","key":"2025060501014317700_CIT0001","first-page":"vdaa178","article-title":"Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study","volume":"3","author":"Habbous","year":"2021","journal-title":"Neurooncol. Adv."},{"issue":"1","key":"2025060501014317700_CIT0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep."},{"issue":"9","key":"2025060501014317700_CIT0003","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"2025060501014317700_CIT0004","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 Part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025060501014317700_CIT0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2023.04.018","article-title":"Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids","volume":"188","author":"Manacorda","year":"2023","journal-title":"Eur J Cancer."},{"key":"2025060501014317700_CIT0006","first-page":"27","article-title":"Brain metastases: epidemiology","volume-title":"Handbook of Clinical Neurology","author":"Ostrom","year":"2018"},{"issue":"12","key":"2025060501014317700_CIT0007","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"2025060501014317700_CIT0008","doi-asserted-by":"crossref","first-page":"e000333","DOI":"10.1136\/jitc-2019-000333","article-title":"Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"J ImmunoTher Cancer."},{"issue":"10","key":"2025060501014317700_CIT0009","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol."},{"issue":"6","key":"2025060501014317700_CIT0010","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s13311-022-01312-w","article-title":"Update on the management of brain metastasis","volume":"19","author":"Singh","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"21","key":"2025060501014317700_CIT0011","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"2025060501014317700_CIT0012","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in Crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J Clin Oncol."},{"key":"2025060501014317700_CIT0013","doi-asserted-by":"crossref","first-page":"105779","DOI":"10.1016\/j.clineuro.2020.105779","article-title":"The risk of developing seizures before and after surgery for brain metastases","volume":"193","author":"Puri","year":"2020","journal-title":"Clin Neurol Neurosurg."},{"issue":"19","key":"2025060501014317700_CIT0014","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1002\/cncr.33085","article-title":"Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases","volume":"126","author":"Steindl","year":"2020","journal-title":"Cancer."},{"key":"2025060501014317700_CIT0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clineuro.2018.08.002","article-title":"Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms","volume":"173","author":"Cacho-D\u00edaz","year":"2018","journal-title":"Clin Neurol Neurosurg."},{"issue":"8","key":"2025060501014317700_CIT0016","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1212\/WNL.0000000000011459","article-title":"Seizures among patients with brain metastases: a population- and institutional-level analysis","volume":"96","author":"Lamba","year":"2021","journal-title":"Neurology."},{"issue":"11","key":"2025060501014317700_CIT0017","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol."},{"issue":"5","key":"2025060501014317700_CIT0018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol."},{"issue":"2","key":"2025060501014317700_CIT0019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/JNS\/2008\/108\/2\/0227","article-title":"Seizure characteristics and control following resection in 332 patients with low-grade gliomas","volume":"108","author":"Chang","year":"2008","journal-title":"J Neurosurg."},{"issue":"7","key":"2025060501014317700_CIT0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/neuonc\/nov032","article-title":"Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review","volume":"17","author":"Koekkoek","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"2025060501014317700_CIT0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11940-020-0613-y","article-title":"Epilepsy in brain metastasis: an emerging entity","volume":"22","author":"Rud\u00e0","year":"2020","journal-title":"Curr Treat Options Neurol"},{"issue":"11","key":"2025060501014317700_CIT0022","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","article-title":"SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors","volume":"23","author":"Walbert","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"2025060501014317700_CIT0023","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.10712","article-title":"Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life","volume":"54","author":"Klein","year":"2003","journal-title":"Ann Neurol."},{"issue":"10172","key":"2025060501014317700_CIT0024","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet."},{"key":"2025060501014317700_CIT0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1528-1157.43.s.6.12.x","article-title":"The psychosocial burden of epilepsy","volume":"43","author":"Baker","year":"2002","journal-title":"Epilepsia."},{"issue":"2","key":"2025060501014317700_CIT0026","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11060-014-1449-7","article-title":"Weight of epilepsy in brain tumor patients","volume":"118","author":"Maschio","year":"2014","journal-title":"J Neurooncol."},{"issue":"9","key":"2025060501014317700_CIT0027","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1470-2045(12)70266-8","article-title":"Epilepsy meets cancer: when, why, and what to do about it","volume":"13","author":"Weller","year":"2012","journal-title":"Lancet Oncol."},{"issue":"7","key":"2025060501014317700_CIT0028","doi-asserted-by":"crossref","first-page":"e0180470","DOI":"10.1371\/journal.pone.0180470","article-title":"Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center","volume":"12","author":"Maschio","year":"2017","journal-title":"PLoS One."},{"key":"2025060501014317700_CIT0029","doi-asserted-by":"crossref","first-page":"967946","DOI":"10.3389\/fneur.2022.967946","article-title":"Impact of epilepsy and its treatment on brain metastasis from solid tumors: a retrospective study","volume":"13","author":"Maschio","year":"2022","journal-title":"Front Neurol."},{"issue":"5","key":"2025060501014317700_CIT0030","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.16880","article-title":"First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid","volume":"62","author":"van der Meer","year":"2021","journal-title":"Epilepsia."},{"issue":"6","key":"2025060501014317700_CIT0031","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"key":"2025060501014317700_CIT0032","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025060501014317700_CIT0033","author":"Sterne"},{"key":"2025060501014317700_CIT0034","first-page":"679","article-title":"Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: radiation therapy oncology group brain metastases study I and II","author":"Carella","year":"1980"},{"issue":"1","key":"2025060501014317700_CIT0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","article-title":"The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group","volume":"6","author":"Borgelt","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2025060501014317700_CIT0036","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10143-021-01560-y","article-title":"Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom","volume":"45","author":"Bahna","year":"2022","journal-title":"Neurosurg Rev."},{"issue":"2","key":"2025060501014317700_CIT0037","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3171\/2023.5.FOCUS23133","article-title":"Association of CDKN2A alterations with increased postoperative seizure risk after resection of brain metastases","volume":"55","author":"Cummins","year":"2023","journal-title":"Neurosurg Focus."},{"issue":"1","key":"2025060501014317700_CIT0038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3171\/2022.3.JNS212285","article-title":"Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases","volume":"138","author":"Garcia","year":"2023","journal-title":"J Neurosurg."},{"issue":"7","key":"2025060501014317700_CIT0039","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s10072-023-06695-y","article-title":"Frequency of seizures in patients with metastatic brain tumors","volume":"44","author":"Huntoon","year":"2023","journal-title":"Neurol Sci."},{"issue":"3","key":"2025060501014317700_CIT0040","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4143\/crt.2011.43.3.160","article-title":"Clinical analysis for brain tumor-related epilepsy during chemotherapy for systemic cancer with single brain metastasis","volume":"43","author":"Kim","year":"2011","journal-title":"Cancer Res Treat"},{"issue":"10","key":"2025060501014317700_CIT0041","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00701-013-1826-6","article-title":"Risk of seizure and its clinical implication in the patients with cerebral metastasis from lung cancer","volume":"155","author":"Lee","year":"2013","journal-title":"Acta Neurochir (Wien)."},{"issue":"1","key":"2025060501014317700_CIT0042","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-009-0069-0","article-title":"Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy","volume":"98","author":"Maschio","year":"2010","journal-title":"J Neurooncol."},{"issue":"4","key":"2025060501014317700_CIT0043","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3171\/2023.2.JNS222778","article-title":"Seizure outcomes following single-fraction versus hypofractionated radiosurgery for brain metastases: a single-center experience","volume":"139","author":"Miller","year":"2023","journal-title":"J Neurosurg."},{"issue":"3","key":"2025060501014317700_CIT0044","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11060-007-9373-8","article-title":"Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors","volume":"84","author":"Newton","year":"2007","journal-title":"J Neurooncol."},{"issue":"3","key":"2025060501014317700_CIT0045","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3171\/2016.2.JNS152855","article-title":"Functional approach using intraoperative brain mapping and neurophysiological monitoring for the surgical treatment of brain metastases in the central region","volume":"126","author":"Sanmillan","year":"2017","journal-title":"J Neurosurg."},{"key":"2025060501014317700_CIT0046","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.wneu.2017.05.028","article-title":"Risk factors for preoperative seizures and loss of seizure control in patients undergoing surgery for metastatic brain tumors","volume":"104","author":"Wu","year":"2017","journal-title":"World Neurosurg"},{"issue":"6","key":"2025060501014317700_CIT0047","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1007\/s10143-021-01504-6","article-title":"Is function-based resection using intraoperative awake brain mapping feasible and safe for solitary brain metastases within eloquent areas","volume":"44","author":"Pelletier","year":"2021","journal-title":"Neurosurg Rev."},{"key":"2025060501014317700_CIT0048","doi-asserted-by":"crossref","first-page":"107033","DOI":"10.1016\/j.eplepsyres.2022.107033","article-title":"Prevalence of seizures in brain tumor: a meta-analysis","volume":"187","author":"Audrey","year":"2022","journal-title":"Epilepsy Res."},{"issue":"5","key":"2025060501014317700_CIT0049","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"van Breemen","year":"2007","journal-title":"Lancet Neurol."},{"issue":"14","key":"2025060501014317700_CIT0050","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol."},{"issue":"10","key":"2025060501014317700_CIT0051","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer."},{"issue":"3","key":"2025060501014317700_CIT0052","first-page":"e567","article-title":"Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone","volume":"111","author":"Dohm","year":"2022","journal-title":"J Neurosurg."},{"issue":"6","key":"2025060501014317700_CIT0053","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3171\/2023.4.JNS2349","article-title":"Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis","volume":"139","author":"Yomo","year":"2023","journal-title":"J Neurosurg."},{"issue":"1","key":"2025060501014317700_CIT0054","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-017-2647-x","article-title":"Imaging changes over 18 months following stereotactic radiosurgery for brain metastases: both late radiation necrosis and tumor progression can occur","volume":"136","author":"Fujimoto","year":"2018","journal-title":"J Neurooncol."},{"issue":"10","key":"2025060501014317700_CIT0055","doi-asserted-by":"crossref","first-page":"e1392","DOI":"10.1212\/WNL.0000000000010190","article-title":"A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis","volume":"95","author":"Huang","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"2025060501014317700_CIT0056","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","article-title":"A systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery and international stereotactic radiosurgery society recommendations","volume":"118","author":"Vellayappan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"11","key":"2025060501014317700_CIT0057","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/neuonc\/noac172","article-title":"Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab","volume":"24","author":"Hertler","year":"2022","journal-title":"Neuro Oncol"},{"key":"2025060501014317700_CIT0058","doi-asserted-by":"crossref","first-page":"199","DOI":"10.36255\/exonpublications.gliomas.2021.chapter12","article-title":"Pathogenesis and management of brain tumor-related epilepsy","volume-title":"Gliomas","author":"Adhikari","year":"2021"},{"issue":"1","key":"2025060501014317700_CIT0059","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3171\/2020.11.JNS202873","article-title":"Brain tumor-related epilepsy and risk factors for metastatic brain tumors: analysis of 601 consecutive cases providing real-world data","volume":"136","author":"Asano","year":"2022","journal-title":"J Neurosurg."},{"issue":"6","key":"2025060501014317700_CIT0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/ana.24522","article-title":"Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: a retrospective observational single center study","volume":"78","author":"Skardelly","year":"2015","journal-title":"Ann Neurol."},{"issue":"3","key":"2025060501014317700_CIT0061","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11060-016-2335-2","article-title":"Incidence of seizure in adult patients with intracranial metastatic disease","volume":"131","author":"Chan","year":"2017","journal-title":"J Neurooncol."},{"issue":"2","key":"2025060501014317700_CIT0062","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/WNP.0000000000000671","article-title":"Seizures in patients with metastatic brain tumors: prevalence, clinical characteristics, and features on EEG","volume":"38","author":"Ajinkya","year":"2021","journal-title":"J Clin Neurophysiol."},{"issue":"5","key":"2025060501014317700_CIT0063","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/neuonc\/noz172","article-title":"Risk factors for the development of epilepsy in patients with brain metastases","volume":"22","author":"Wolpert","year":"2020","journal-title":"Neuro Oncol"},{"issue":"10","key":"2025060501014317700_CIT0064","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1111\/epi.17379","article-title":"Postoperative progression of brain metastasis is associated with seizures","volume":"63","author":"Wolpert","year":"2022","journal-title":"Epilepsia."},{"key":"2025060501014317700_CIT0065","first-page":"267","article-title":"Epilepsy and brain tumors","volume-title":"Handbook of Clinical Neurology","author":"Englot","year":"2016"},{"issue":"1","key":"2025060501014317700_CIT0066","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s42466-022-00205-9","article-title":"Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication","volume":"4","author":"Seidel","year":"2022","journal-title":"Neurol Res Pract"},{"issue":"3","key":"2025060501014317700_CIT0067","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.seizure.2011.12.016","article-title":"The pathogenesis of tumor-related epilepsy and its implications for clinical treatment","volume":"21","author":"You","year":"2012","journal-title":"Seizure."},{"key":"2025060501014317700_CIT0068","doi-asserted-by":"crossref","first-page":"120584","DOI":"10.1016\/j.jns.2023.120584","article-title":"Epilepsy and brain tumors: two sides of the same coin","volume":"446","author":"Aronica","year":"2023","journal-title":"J Neurol Sci."},{"issue":"1","key":"2025060501014317700_CIT0069","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","article-title":"Tumor-related epilepsy: epidemiology, pathogenesis and management","volume":"139","author":"Chen","year":"2018","journal-title":"J Neurooncol."},{"key":"2025060501014317700_CIT0070","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.phrs.2020.104786","article-title":"Epileptogenesis and oncogenesis: an antineoplastic role for antiepileptic drugs in brain tumours","volume":"156","author":"Cucchiara","year":"2020","journal-title":"Pharmacol Res."},{"key":"2025060501014317700_CIT0071","doi-asserted-by":"crossref","first-page":"983878","DOI":"10.3389\/fonc.2022.983878","article-title":"Tumor microenvironment and exosomes in brain metastasis: molecular mechanisms and clinical application","volume":"12","author":"Aili","year":"2022","journal-title":"Front Oncol."},{"issue":"3","key":"2025060501014317700_CIT0072","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1073\/pnas.1322098111","article-title":"Human breast cancer metastases to the brain display GABAergic properties in the neural niche","volume":"111","author":"Neman","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7775","key":"2025060501014317700_CIT0073","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-019-1576-6","article-title":"Synaptic proximity enables NMDAR signalling to promote brain metastasis","volume":"573","author":"Zeng","year":"2019","journal-title":"Nature."},{"issue":"2","key":"2025060501014317700_CIT0074","doi-asserted-by":"crossref","first-page":"e0211644","DOI":"10.1371\/journal.pone.0211644","article-title":"AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro","volume":"14","author":"Lange","year":"2019","journal-title":"PLoS One."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npae103\/60971881\/npae103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/3\/376\/60971881\/npae103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/3\/376\/60971881\/npae103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:02:00Z","timestamp":1749099720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/12\/3\/376\/7830528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":74,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npae103","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,10,22]]}}}